Advancing Diagnostics & Biomarkers to Definitively Characterize the B-Cell Repertoire & Success of Immune Resetting Therapeutics in a Clinical Setting

Join this workshop to explore how immune resetting is being measured in the clinic:

• Highlighting the disconnect between B-cell levels in peripheral blood and their persistence in the lymph nodes following conventional antibody therapies
• Discussing the necessity of lymph node biopsies as a direct, ex vivo method to accurately quantify the depth of depletion to address the disruption of the follicular pathway in the lymph nodes to provide a measure of therapeutic effects
• Comparing the tissue outcomes across different therapeutic modalities linking deep lymphoid tissue depletion to the potential for sustained, long-term remission
• Effectively analyzing the B-cell repertoire to gain insights into effectiveness of the treatment after resetting the immune system
• Utilizing B-cell receptor gene sequencing to precisely track and confirm the deep and sustained elimination of these initial pathogenic B-cells following immuneresetting therapy
• Ensuring newly generated B-cells are free of the original pathogenic B-cells as molecular evidence for the restoration of self-tolerance
• Establishing molecular signatures that predict long-term remission